Torrent Pharma walks back US growth targets to single digits
Management abandons its $200 million annual revenue goal, citing a slower two-year outlook for the US market.
— 2 earlier stories on Torrent Pharmaceuticals Ltd. →What's new with Torrent Pharmaceuticals Ltd.
- US revenue growth target downgraded to single digits for the next two years.
- Semaglutide launch captured 38% generic market share in its first month.
- JB Pharma acquisition cost savings targeted at ₹400-450 cr over three years.
Why this matters for Torrent Pharmaceuticals Ltd.
The retreat from the $200 million US revenue goal marks a change in the company's growth story. Whether domestic gains can offset this international cooling is the next test.
What we're watching
- Sustainability of Semaglutide market share in India against new competition.
- Actual realization of cost savings from the JB Pharma acquisition.
- Quarterly US revenue figures to verify the single-digit guidance.
The full read
Torrent Pharmaceuticals used its post-results conference call to reset expectations for its US business. Management pulled back from its prior goal of crossing $200 million in annual US revenue, guiding instead for single-digit growth over the next two years. The shift marks a slowdown in international expectations. Domestic operations provide a counter-narrative. The Semaglutide launch generated ₹17 crore in April, capturing 38% of the generic market. The JB Pharma acquisition is tracking ahead of schedule, with management now targeting ₹400-450 crore in cost savings over a three-year period. Domestic business targets mid-teens organic growth, provided no external demand shocks arise. With the US engine cooling, the company relies on domestic product launches and cost efficiencies. The open question is how effectively these domestic gains cover the lost US momentum.